<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03443661</url>
  </required_header>
  <id_info>
    <org_study_id>CH-GI-086</org_study_id>
    <nct_id>NCT03443661</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Pilot Phase II Study of Neoadjuvant Triplet Chemotherapy Regimen （FOLFOXIRI） in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aiping Zhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the feasibility, safety and efficacy of triplet regimen of
      neoadjuvant chemotherapy in patients with locally advanced rectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this pilot phase II study, the investigators enrolled Chinese adults(age 18 to 70 years)
      with locally advanced stage II/III rectal cancer. The neuadjuvant chemotherapy regimen is :
      oxaliplatin 85 mg/m2 and irinotecan 150 mg/m2, combined with 5FU 2,400 mg/m2 by 46 h
      infusion, repeated at 2week intervals for 5 cycles. Total mesorectal excision was scheduled
      4-5 weeks after completion of neoadjuvant treatment and followed by a further 7 cycles of
      mFOLFOX or 4 cycles of XELOX. Primary outcome measures of this phase II trial were
      feasibility, safety, tolerance and efficacy of neoadjuvant treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 6, 2016</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pCR</measure>
    <time_frame>1 year</time_frame>
    <description>Pathological complete response according to Mandard tumor regression grading</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 year</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>locoregional recurrence rate</measure>
    <time_frame>1 year</time_frame>
    <description>locoregional recurrence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>1 year</time_frame>
    <description>Including adverse events during neoadjuvant chemotherapy,surgery and perioperative complications</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOXIRI</intervention_name>
    <description>oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals</description>
    <arm_group_label>FOLFOXIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed locally advanced rectal cancer;

          2. 18-70 years ；

          3. Clinicalstage:T3,4a,N0,M0;T1-4a,N+,M0;

          4. Tumor from anus &gt;5cm and ≤15cm;

          5. ECOG=0-1;

          6. Available organ function:ALT≤1.5xULN;AST≤1.5xULN;TBIL≤1.0xULN;
             NEUT≥2×109/L;PLT≥100×109/L;Hb≥90g/L;Creatinine≤1.0xULN;

          7. Informed consent;

          8. UGT1A1:UGT1A1*1/UGT1A1*1,UGT1A1*1/UGT1A1*28,UGT1A1*1/UGT1A1*6;

        Exclusion Criteria:

          1. Clinical stage T4b or unresectable disease;

          2. History of pelvic radiotherapy;

          3. History of chemotherapy within 5 years;

          4. History of chronic diarrhea;

          5. Tumor causes intestinal obstruction, intestinal perforation, and severe bleeding;

          6. Hepatitis B surface antigen positive; Hepatitis C virus infection; Cirrhosis of the
             liver for any cause;

          7. UGT1A1:UGT1A1*28/UGT1A1*28,UGT1A1*6/UGT1A1*6;

          8. Other cancers in the past 5 years, except for cervical carcinoma in situ or
             non-melanoma skin cancer;

          9. Myocardial infarction (in the last 6 months), severe instability angina, congestive
             heart failure; interstitial pneumonia,pulmonary fibrosis, uncontrolled diabetes, renal
             insufficiency;

         10. Mental illness;Pregnant or lactating women;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aiping Zhou, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>China National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aiping Zhou, Doctor</last_name>
    <phone>+86 13691161998</phone>
    <email>zhouap1825@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wen Zhang, Doctor</last_name>
    <phone>+86 18611643302</phone>
    <email>wenwen0605@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center/Cancer Hospital, Chinese ACademy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou, Doctor</last_name>
      <phone>+86 13691161998</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Aiping Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2018</study_first_submitted>
  <study_first_submitted_qc>February 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>5-Fluorouracil</keyword>
  <keyword>rectal cancer</keyword>
  <keyword>irinotecan</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

